Boston Scientific Acquires SVG Embolic Protection At Reduced Cost
This article was originally published in The Gray Sheet
Executive Summary
Rubicon Medical will forego a higher payment for its embolic filter technology than originally expected from Boston Scientific, opting instead for immediate cash flow to support commercialization
You may also be interested in...
Carotid Stent, AAA Market Entry: Boston Scientific Moves On Earn-Outs
Boston Scientific intends to acquire carotid stent manufacturer EndoTex by year-end, following an anticipated FDA approval of NexStent
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.